Effects of Vaporized Marijuana on Neuropathic Pain
What it found
Results are posted in the registry, but without a statistical test of the main measure. See the numbers below.
What was tested
Treatment tested
- Mild dose cannabis
- Low dose cannabis
Placebo or sham
- Cannabis
Results by group
Participants With 30% or Greater Reduction in Pain Intensity
baseline to six hours
| Group | Value | Interval | Number analysed |
|---|---|---|---|
| Mild Dose Cannabis | 61 percentage of participants | 45–75 | 36 |
| Low Dose Cannabis | 57 percentage of participants | 41–71 | 37 |
| Placebo Cannabis | 26 percentage of participants | 15–42 | 38 |
Mild Dose Cannabis
Low Dose Cannabis
Placebo Cannabis
Values as posted on ClinicalTrials.gov. Outcomes measured differently across trials are not directly comparable.
Safety
| Group | Participants at risk | Serious adverse events | Deaths |
|---|---|---|---|
| Mild Dose Cannabis | 36 | 0 (0.0%) | |
| Low Dose Cannabis | 37 | 0 (0.0%) | |
| Placebo Cannabis | 38 | 0 (0.0%) |
As posted on ClinicalTrials.gov. Serious adverse events include any serious health event during the trial, whether or not the treatment caused it.
What it measured
Main measures
Participants With 30% or Greater Reduction in Pain Intensity
baseline to six hours
Pain
Other measures (1)
Visual Analogue Scale Pain Intensity Scores for Baseline and up to 5 Hours Following Administration of Vaporized Cannabis
baseline to six hours
Pain
Who could take part
MS (type not specified) · 18 to 70
Inclusion Criteria: * Age greater than 18 and less than 70 * Visual Analogue Scale (VAS pain intensity) greater than 3/10 * A negative urine drug screening test, i.e., no evidence of IV drug abuse * Neuropathic pain due to reflex sympathetic dystrophy, peripheral neuropathy, post-herpetic neuralgia, post-stroke pain, multiple sclerosis or spinal cord injury Exclusion Criteria: * Presence of another painful condition of greater severity than the neuropathic pain condition which is being studied. * Subjects with moderate-severe major depression, bipolar/mania, bipolar II/hypomania and schizophrenia or schizoaffective disorder. * Unstable Type 1 or 2 diabetes defined as blood glucose more than 156 mg/dl * History of traumatic brain injury * Uncontrolled medical condition, including coronary artery disease, hypertension, cerebrovascular disease, asthma, tuberculosis (TB), chronic obstructive pulmonary disease (COPD), opportunistic infection, malignancy requiring active treatment, active substance abuse (alcohol or injection drugs). * Current use of marijuana (e.g., within 30 days of randomization) * Pregnancy as ascertained by a self-report and a mandatory commercial pregnancy test.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
This study theorized that a low dose of vaporized cannabis could alleviate nerve injury pain.
Papers
Results
Low-dose vaporized cannabis significantly improves neuropathic pain.J Pain · 2013
Background
Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008 Jun;9(6):506-21. doi: 10.1016/j.jpain.2007.12.010. Epub 2008 Apr 10.
Loading reviews and guidelines…
Related trials
- ICE Trial
Phase 4 · Ongoing (inferred)
Still running
- A Study to Investigate Arbaclofen ER Tablets for the Trea…
Phase 3 · Not yet recruiting
Still running
- Cannabis (THC vs. CBD) in Multiple Sclerosis
Phase 2 · Recruiting
Still running
- ICE
Phase 4 · Recruiting
Still running
- Mechanisms of Cannabidiol in Persons With MS: the Role of…
Phase 2 · Recruiting
Still running
- AntibioBoNTA
Phase 3 · Ongoing
Still running
History
Started
Dec 2009
Main results due
Nov 2012
Finished
Nov 2012
Results posted
Apr 2013
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error